# EDGAR Filing Document

**Accession Number:** 0001964437
**File Stem:** 0001964437-25-000011
**Filing Date:** 2025-8
**Character Count:** 16571
**Document Hash:** d3a2435b5537164fcbb596dbdb7a3917
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001964437-25-000011.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001964437-25-000011

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Saturn V Capital Management LP
- **CENTRAL INDEX KEY:** 0001964437

**ORGANIZATION NAME:**
- **EIN:** 862769060
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-22863
- **FILM NUMBER:** 251278330

**BUSINESS ADDRESS:**
- **STREET 1:** 919 CONGRESS AVENUE
- **STREET 2:** SUITE 830
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701
- **BUSINESS PHONE:** 415-738-4435

**MAIL ADDRESS:**
- **STREET 1:** 919 CONGRESS AVENUE
- **STREET 2:** SUITE 830
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Saturn V Capital Management LLC
- **DATE OF NAME CHANGE:** 20230201

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001964437

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Saturn V Capital Management LP

**Address:** 919 CONGRESS AVENUE, AUSTIN, TX 78701

**Telephone number:** 415-738-4435

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-22863

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 254900S5UTVYRQGJSH84

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                   | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                   | VOTE CATEGORY   |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| CELCUITY INC.                    | 15102K100 | 05/13/2025     | To approve, by a non-binding and advisory vote, compensation of the named executive officers.                                                                                                                                                      | COMPENSATION    |         821897 |                0 | FOR         |                                   821897 | FOR                         |  |
| CELCUITY INC.                    | 15102K100 | 05/13/2025     | To approve an amendment to the Company's Amended and Restated 2017 Stock Incentive Plan increasing the number of shares available for issuance under the plan by 3,000,000.                                                                        | COMPENSATION    |         821897 |                0 | FOR         |                                   821897 | FOR                         |  |
| SYNDAX PHARMACEUTICALS, INC      | 87164F105 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 proxy statement.                                                                                                            | COMPENSATION    |         581300 |                0 | FOR         |                                   581300 | FOR                         |  |
| MERUS N.V.                       | N5749R100 | 05/21/2025     | Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.                                                                                                                                        | COMPENSATION    |         231740 |                0 | FOR         |                                   231740 | FOR                         |  |
| ARGENX SE                        | 04016X101 | 05/27/2025     | The 2024 remuneration report                                                                                                                                                                                                                       | COMPENSATION    |          10418 |                0 | FOR         |                                    10418 | FOR                         |  |
| ARGENX SE                        | 04016X101 | 05/27/2025     | Adoption of the remuneration policy                                                                                                                                                                                                                | COMPENSATION    |          10418 |                0 | FOR         |                                    10418 | FOR                         |  |
| COGENT BIOSCIENCES, INC.         | 19240Q201 | 06/04/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                         | COMPENSATION    |         665306 |                0 | FOR         |                                   665306 | FOR                         |  |
| NEWAMSTERDAM PHARMA COMPANY N.V. | N62509109 | 06/04/2025     | Non-binding, advisory vote to approve the 2024 compensation of named executive officers.                                                                                                                                                           | COMPENSATION    |          96874 |                0 | FOR         |                                    96874 | FOR                         |  |
| NEWAMSTERDAM PHARMA COMPANY N.V. | N62509109 | 06/04/2025     | Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers.                                                                                                             | COMPENSATION    |          96874 |                0 | FOR         |                                    96874 | FOR                         |  |
| AMYLYX PHARMACEUTICALS, INC.     | 03237H101 | 06/05/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                                    | COMPENSATION    |          11135 |                0 | FOR         |                                    11135 | FOR                         |  |
| ABIVAX SA                        | 00370M103 | 06/06/2025     | APPROVAL OF THE REMUNERATION ELEMENTS REFERRED TO IN SECTION I OF ARTICLE L. 22-10-9 OF THE FRENCH COMMERCIAL CODE, PURSUANT TO ARTICLE L. 22-10-34 OF THE FRENCH COMMERCIAL CODE                                                                  | COMPENSATION    |         552926 |                0 | FOR         |                                   552926 | FOR                         |  |
| ABIVAX SA                        | 00370M103 | 06/06/2025     | APPROVAL OF THE REMUNERATION ELEMENTS PAID DURING OR ALLOCATED IN RESPECT OF THE FINANCIAL YEAR 2024 TO MR. MARC DE GARIDEL IN HIS CAPACITY AS ACTING CHAIRMAN OF THE BOARD OF DIRECTORS AND CHIEF EXECUTIVE OFFICER                               | COMPENSATION    |         552926 |                0 | FOR         |                                   552926 | FOR                         |  |
| ABIVAX SA                        | 00370M103 | 06/06/2025     | APPROVAL OF THE REMUNERATION ELEMENTS PAID DURING OR ALLOCATED IN RESPECT OF THE FINANCIAL YEAR 2024 TO MRS. SYLVIE GREGOIRE IN HER CAPACITY AS CHAIRWOMAN OF THE BOARD OF DIRECTORS                                                               | COMPENSATION    |         552926 |                0 | FOR         |                                   552926 | FOR                         |  |
| ABIVAX SA                        | 00370M103 | 06/06/2025     | APPROVAL OF THE INFORMATION ON THE REMUNERATION OF CORPORATE OFFICERS CONTAINED IN THE CORPORATE GOVERNANCE REPORT AND REFERRED TO IN SECTION I OF ARTICLE L.22-10-9 OF THE FRENCH COMMERCIAL CODE                                                 | COMPENSATION    |         552926 |                0 | FOR         |                                   552926 | FOR                         |  |
| ABIVAX SA                        | 00370M103 | 06/06/2025     | APPROVAL OF THE REMUNERATION POLICY APPLICABLE TO THE CHAIRMAN OF THE BOARD OF DIRECTORS                                                                                                                                                           | COMPENSATION    |         552926 |                0 | FOR         |                                   552926 | FOR                         |  |
| ABIVAX SA                        | 00370M103 | 06/06/2025     | APPROVAL OF THE REMUNERATION POLICY APPLICABLE TO THE CHIEF EXECUTIVE OFFICER                                                                                                                                                                      | COMPENSATION    |         552926 |                0 | FOR         |                                   552926 | FOR                         |  |
| ABIVAX SA                        | 00370M103 | 06/06/2025     | APPROVAL OF THE REMUNERATION POLICY APPLICABLE TO DIRECTORS                                                                                                                                                                                        | COMPENSATION    |         552926 |                0 | FOR         |                                   552926 | FOR                         |  |
| CRINETICS PHARMACEUTICALS INC.   | 22663K107 | 06/11/2025     | To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.           | COMPENSATION    |          32765 |                0 | FOR         |                                    32765 | FOR                         |  |
| DISC MEDICINE, INC.              | 254604101 | 06/11/2025     | To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.                                                                                                                                     | COMPENSATION    |         232449 |                0 | FOR         |                                   232449 | FOR                         |  |
| DISC MEDICINE, INC.              | 254604101 | 06/11/2025     | To recommend, by a non-binding advisory vote, the frequency of future advisory votes on the compensation paid to the Company's named executive officers.                                                                                           | COMPENSATION    |         232449 |                0 | FOR         |                                   232449 | FOR                         |  |
| OCULAR THERAPEUTIX, INC.         | 67576A100 | 06/11/2025     | To approve an advisory vote on named executive officer compensation.                                                                                                                                                                               | COMPENSATION    |         328049 |                0 | FOR         |                                   328049 | FOR                         |  |
| OCULAR THERAPEUTIX, INC.         | 67576A100 | 06/11/2025     | To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 8,750,000 shares.                                                           | COMPENSATION    |         328049 |                0 | FOR         |                                   328049 | FOR                         |  |
| OCULAR THERAPEUTIX, INC.         | 67576A100 | 06/11/2025     | To approve an amendment and restatement of the Ocular Therapeutix, Inc. 2014 Employee Stock Purchase Plan to increase the number of shares of common stock issuable thereunder by 2,000,000 shares and to remove the annual "evergreen" provision. | COMPENSATION    |         328049 |                0 | FOR         |                                   328049 | FOR                         |  |
| VAXCYTE, INC.                    | 92243G108 | 06/12/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                         | COMPENSATION    |           4145 |                0 | FOR         |                                     4145 | FOR                         |  |
| CENTESSA PHARMACEUTICALS PLC     | 152309100 | 06/20/2025     | To receive and approve, on an advisory basis, the Company's U.K. statutory directors' remuneration report for the financial year ended December 31, 2024.                                                                                          | COMPENSATION    |         638426 |                0 | FOR         |                                   638426 | FOR                         |  |
| CENTESSA PHARMACEUTICALS PLC     | 152309100 | 06/20/2025     | To receive and approve the Directors' Remuneration Policy as set out on pages A-3 to A-25 of the Company's UK statutory directors' remuneration report for the financial year ended December 31, 2024.                                             | COMPENSATION    |         638426 |                0 | FOR         |                                   638426 | FOR                         |  |
| SILENCE THERAPEUTICS PLC         | 82686Q101 | 06/26/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.                                                                                                                           | COMPENSATION    |         249799 |                0 | FOR         |                                   249799 | FOR                         |  |
| SILENCE THERAPEUTICS PLC         | 82686Q101 | 06/26/2025     | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers.                                                                                                      | COMPENSATION    |         249799 |                0 | FOR         |                                   249799 | FOR                         |  |
| SILENCE THERAPEUTICS PLC         | 82686Q101 | 06/26/2025     | To approve our directors' remuneration report for the year ended December 31, 2024.                                                                                                                                                                | COMPENSATION    |         249799 |                0 | FOR         |                                   249799 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Saturn V Capital Management LP

**By (Signature):** Douglas K Edwards

**By (Printed Signature):** Douglas K Edwards

**By (Title):** Chief Financial Officer

**Date:** 08/29/2025